NTI-55

**NTI-55** is a preclinical, tumor-targeted Nammisome lipid-nanoparticle immunotherapy developed by Nammi Therapeutics for solid tumors. It co-formulates proprietary lipid prodrugs comprising a Toll-like receptor 7 agonist and an adenosine A2A receptor inhibitor, aiming to activate innate antitumor immunity while relieving adenosine-mediated immunosuppression in the tumor microenvironment. Nammi reported preclinical antitumor validation and described the nanoparticle approach as reducing systemic exposure while synchronizing drug delivery and activation at tumor sites. ([nammirx.com](https://www.nammirx.com/post/nammi-therapeutics-unveils-two-novel-immunotherapies-at-aacr-conference))